AstraZeneca Deals Boost Respiratory Business, Chinese Operations – Wall Street Journal


Wall Street Journal

AstraZeneca Deals Boost Respiratory Business, Chinese Operations
Wall Street Journal
Both deals strengthen areas in which AstraZeneca intends to grow. The company has spent the past few years intensifying its focus on its “growth platforms,” which include respiratory drugs and emerging markets. At the same time, it has sold or licensed
AstraZeneca boosts respiratory unit with $575 million Takeda dealReuters

all 35 news articles »

Read More…

Share This: